Navigation Links
American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD

Endorsed by the American Academy of Child and Adolescent Psychiatry, the American College of Cardiology, Children and Adults with Attention-Deficit/Hyperactivity Disorder and the National Initiative for Children's Healthcare Quality

DALLAS, May 16 /PRNewswire-USNewswire/ -- The American Heart Association released on April 21, 2008 a statement about cardiovascular evaluation and monitoring of children receiving drugs for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). As a result of language in the news release and the statement as published, there have been conflicting interpretations of the recommendations regarding the use of an electrocardiogram (ECG) in assessing children with ADHD who may need treatment with medications. The purpose of this joint advisory of the American Academy of Pediatrics (AAP) and the American Heart Association (AHA) is to clarify the recommendations.

-- The scientific statement included a review of data that show children

with heart conditions have a higher incidence of ADHD.

-- Because certain heart conditions in children may be difficult (even, in

some cases, impossible) to detect, the AAP and AHA feel that it is

prudent to carefully assess children for heart conditions who need to

receive treatment with drugs for ADHD.

-- Obtaining a patient and family health history and doing a physical exam

focused on cardiovascular disease risk factors (Class I recommendations

in the statement) are recommended by the AAP and AHA for assessing

patients before treatment with drugs for ADHD.

-- Acquiring an ECG is a Class IIa recommendation. This means that it is

reasonable for a physician to consider obtaining an ECG as part of the

evaluation of children being considered for stimulant drug therapy, but

this should be at the physician's judgment, and it is not mandatory

to obtain one.

-- Treatment of a patient with ADHD should not be withheld because an ECG

is not done. The child's physician is the best person to make the

assessment about whether there is a need for an ECG.

-- Medications that treat ADHD have not been shown to cause heart

conditions nor have they been demonstrated to cause sudden cardiac

death. However, some of these medications can increase or decrease

heart rate and blood pressure. While these side effects are not usually

considered dangerous, they should be monitored in children with heart

conditions as the physician feels necessary.

An erratum to the statement has been developed to clarify the language and to assure that the intent is clear to all readers. This is available at: DC1.

This clarification has been endorsed by the American Academy of Child and Adolescent Psychiatry, the American College of Cardiology, Children and Adults with Attention-Deficit/Hyperactivity Disorder and the National Initiative for Children's Healthcare Quality.

SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting
2. Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
3. Statement from Larry Minnix, President & CEO American Association of Homes and Services for the Aging, On the Government Accountability Offices (GAO) Nursing Home Oversight Report
4. American Red Cross Vindicated in J&J Lawsuit
5. The American Red Cross Commits $10 Million to Assist China Earthquake Survivors
6. Americans must consider cost and effectiveness when comparing and choosing medical interventions
7. American Red Cross Supports China and Myanmar Relief Efforts
8. American Diabetes Wholesale Launches Affiliate Program
9. The American College of Cardiology, American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device-Based Therapy Guidelines
10. Geneticists at the American Museum of Natural History trace the evolution of St. Louis encephalitis
11. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: